{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:25:48Z","timestamp":1794885948247,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pmedr.2026.103548","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:26:51Z","timestamp":1781994411000},"page":"103548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies"],"prefix":"10.1016","volume":"68","author":[{"given":"Rongxia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pmedr.2026.103548_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17101624","article-title":"Anti-obesity medications and the risk of obesity-related cancers in older women: a propensity score matching analysis of 2007-2015 SEER-Medicare data","volume":"17","author":"Abdelgadir","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pmedr.2026.103548_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.pmedr.2026.103548_bb0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.pmedr.2026.103548_bb0020","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.7326\/ANNALS-24-02718","article-title":"Trends in Cancer incidence in younger and older adults\u202f: an international comparative analysis","volume":"178","author":"Berrington de Gonzalez","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pmedr.2026.103548_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pmedr.2026.103548_bb0030","doi-asserted-by":"crossref","first-page":"04205","DOI":"10.7189\/jogh.14.04205","article-title":"Global obesity epidemic and rising incidence of early-onset cancers","volume":"14","author":"Chen","year":"2024","journal-title":"J. Glob. Health"},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0035","first-page":"12","article-title":"Early GLP-1 agonist use and Cancer risk in type 2 diabetes: a real-world data cohort study","volume":"34","author":"Chuang","year":"2025","journal-title":"Oncol. Res."},{"issue":"10","key":"10.1016\/j.pmedr.2026.103548_bb0040","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and Cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.pmedr.2026.103548_bb0045","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pmedr.2026.103548_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2026.101459","article-title":"Impact of type 2 diabetes on malignancies of the female reproductive system","volume":"108","author":"Espinoza","year":"2026","journal-title":"Mol. Asp. Med."},{"issue":"3","key":"10.1016\/j.pmedr.2026.103548_bb0055","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/oby.24219","article-title":"Global cancer burden attributable to excess body weight, 1990 to 2021, decomposed by population size, aging, and epidemiological change","volume":"33","author":"Feng","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-022-03851-4","article-title":"Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer","volume":"21","author":"Huang","year":"2023","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.pmedr.2026.103548_bb0065","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1111\/dom.70090","article-title":"Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight\/obesity: a real-world observational study","volume":"27","author":"Ipaye","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.pmedr.2026.103548_bb0070","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.3390\/cancers12123860","article-title":"Obesity epidemic-the underestimated risk of endometrial Cancer","volume":"12","author":"Kiesel","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.pmedr.2026.103548_bb0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for Cancer with glucagon-like Peptide-1 receptor agonists and dual agonists\u202f: a systematic review and Meta-analysis","volume":"179","author":"Ko","year":"2026","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010078","article-title":"Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients","volume":"17","author":"Levy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13046-023-02740-y","article-title":"Host obesity alters the ovarian tumor immune microenvironment and impacts response to standard of care chemotherapy","volume":"42","author":"Liu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.pmedr.2026.103548_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/oby.24366","article-title":"Association of Glucagon-like Peptide-1 receptor agonists with Cancer risk in older adults with type 2 diabetes","author":"Lu","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"10.1016\/j.pmedr.2026.103548_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/genes16111352","article-title":"GLP-1 receptor agonists in solid tumour therapy: exploring their anticancer potential and underlying molecular pathways","volume":"16","author":"Lucente","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pmedr.2026.103548_bb0105","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pmedr.2026.103548_bb0110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers15020485","article-title":"Obesity and Cancer: a current overview of epidemiology, pathogenesis, outcomes, and management","volume":"15","author":"Pati","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.pmedr.2026.103548_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40264-025-01551-8","article-title":"Incretin-based drugs and the incidence of endometrial Cancer among people with type 2 diabetes: active comparator new-user design","volume":"48","author":"Rothman","year":"2025","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.pmedr.2026.103548_bb0120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41416-021-01393-y","article-title":"Targeting obesity-related dysfunction in hormonally driven cancers","volume":"125","author":"Rubinstein","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.pmedr.2026.103548_bb0125","doi-asserted-by":"crossref","first-page":"1323399","DOI":"10.3389\/fimmu.2023.1323399","article-title":"Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk","volume":"14","author":"Shea","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.pmedr.2026.103548_bb0130","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.pmedr.2026.103548_bb0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-025-01750-x","article-title":"The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials","volume":"18","author":"Tseng","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.pmedr.2026.103548_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.pmedr.2026.103548_bb0150","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, Meta-analysis, and Meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pmedr.2026.103548_bb0155","doi-asserted-by":"crossref","first-page":"e2558205","DOI":"10.1001\/jamanetworkopen.2025.58205","article-title":"GLP-1 receptor agonists plus progestins and endometrial cancer risk in nonmalignant uterine diseases","volume":"9","author":"Yen","year":"2026","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.pmedr.2026.103548_bb0160","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Preventive Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335526001762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335526001762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:40:41Z","timestamp":1784389241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211335526001762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S2211335526001762"],"URL":"https:\/\/doi.org\/10.1016\/j.pmedr.2026.103548","relation":{},"ISSN":["2211-3355"],"issn-type":[{"value":"2211-3355","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmedr.2026.103548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103548"}}